Evidence map›Paper›PMID 16250263›Full record

ReviewClinical cardiology2005

High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease.

Edward T H Yeh

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Clinical cardiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01410604 (Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01410604 phase4completedstarted 2007, after this paper: background citation

Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial

Ran2007Enrolled31Registered outcomes8Posted comparisons0ConditionsObesityArmsMetformin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Effect of welding fumes on the cardiovascular system: a six-year longitudinal study.Scandinavian journal of work, environment & health · 2021
    Article
  13. A Control-Theoretic Model of Atherosclerosis.International journal of molecular sciences · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Carotid artery intima-media thickness and erectile dysfunction in patients with metabolic syndrome.Medical science monitor : international medical journal of experimental and clinical research · 2014
    Article
  19. Harsh parenting and adolescent health: a longitudinal analysis with genetic moderation.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2014
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Edward T H YehDepartment of Cardiology, University of Texas-MD Anderson Cancer Center, Houston, TX 77030-4095, USA. etyeh@mdanderson.org
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Almost half of first cardiovascular events occur in individuals with no known risk factors. Attempts in the last decade to predict cardiovascular risk more accurately have led to the emergence of a novel risk factor, C-reactive protein (CRP), which has proved to be as good a risk predictor as low-density lipoprotein cholesterol. C-reactive protein is an index of inflammation that is now believed to promote directly all stages of atherosclerosis, including plaque rupture. As measured by high-sensitivity assays, high-sensitivity CRP (hs-CRP) also independently predicts recurrent events in patients with known coronary artery diseases. Recent evidence implicates hs-CRP, and thus inflammation, in the metabolic syndrome and diabetes mellitus, particularly in women. As a clinical tool for cardiovascular risk assessment, hs-CRP testing enhances information provided by lipid screening or global risk assessment. Statin therapy and other interventions can lower hs-CRP. Whether or not such reductions can prevent cardiovascular events is under investigation.

Indexed as

BiomarkersCardiovascular DiseasesCholesterol, LDLC-Reactive ProteinHumansRisk AssessmentRisk Reduction BehaviorSensitivity and SpecificityBiomarkersCholesterol, LDLC-Reactive Protein

Identifiers

PMID16250263
PMCPMC6654463
OpenAlexW2029313658

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.